|
|
|
Sunday, February 12, 2006 — 7:30 PM — International South
|
- Drug-targeted Therapies and Predictive Prognosis: Changing Role of the Pathologist
|
|
Moderator:
|
S. Terence Dunn, University of Oklahoma, Oklahoma City, OK
|
|
|
Disclosure:
|
Dr. Thomas M. Williams indicated he is a consultant for Exagen Diagnostics Company. The other speakers had nothing to disclose. The Academy has also required that the speakers disclose any off label uses of pharmaceutical products or medical devices prior to their presentation.
|
 Click here to download handout in 1-per-page format for the entire meeting (496KB)
Click here to download handout in 6-per-page format for the entire meeting (717KB)
Click any blue title below to display and print the handout for individual lecture(s):
| 7:00 | Introduction - S. Terence Dunn, University of Oklahoma, Oklahoma City, OK |
| 7:15 | Molecular Monitoring Strategies to Track Response to BCR—ABL Kinase Inhibitors in CML - Dan Jones, UT MD Anderson Cancer Center, Houston, TX |
| 7:50 | EGFR Testing in 2006: What Tumors, What Assays, and What to Report? - Jennifer L. Hunt, University of Pittsburgh Medical Center, Pittsburgh, PA |
| 8:25 | Molecular Markers for Targeted Therapy and Prediction of Prognosis in Breast Cancer - Thomas M. Williams, University of New Mexico School of Medicine, Albuquerque, NM |
| The goals of the talks are as follows. Dr. Jones - to survey the different methodologies currently in use to monitor for imatinib resistance in CML samples. Dr. Hunt - to understand the different ways of measuring altered EGFR and the assays utilized; to know which tumors can be tested for EGFR, the clinical significance of the results, and which assays should be used for each tumor type. Dr. Williams - Review known and emerging biomarkers useful in predicting outcome in breast cancer. |
|
|
|
